Teodorico G Exconde Sr., Surgery Medicare: Not Enrolled in Medicare Practice Location: 18697 Bagley Road, Middleburg Heights, OH 44130 Phone: 440-816-8740 Fax: 440-816-4635 |
Pamela Li, M.D. Surgery - Surgical Oncology Medicare: Accepting Medicare Assignments Practice Location: 18697 Bagley Rd, Middleburg Heights, OH 44130 Phone: 440-617-4840 Fax: 162-018-6352 |
Ferdinand M Plecha, M.D. Surgery - Vascular Surgery Medicare: Accepting Medicare Assignments Practice Location: 7255 Old Oak Blvd, Stec108, Middleburg Heights, OH 44130 Phone: 440-816-2786 Fax: 440-816-5454 |
Gregory J Rogers, M.D. Surgery - Vascular Surgery Medicare: Accepting Medicare Assignments Practice Location: 7255 Old Oak Blvd, Ste 108, Middleburg Heights, OH 44130 Phone: 440-816-2786 Fax: 440-816-5454 |
Ahmad H. Shatila, M. D. Surgery - Surgical Oncology Medicare: Not Enrolled in Medicare Practice Location: 18660 East Bagly Rd, Bldg #2 Suite #305, Middleburg Heights, OH 44130 Phone: 440-234-9338 |
News Archive
The signaling molecule interleukin-2 (IL-2) has long been known to have powerful effects on the immune system, but efforts to harness it for therapeutic purposes have been hampered by serious side effects.
At least forty per cent of UK people with learning disabilities are suffering from hearing loss, but new research shows they are unlikely to be diagnosed.
The California Institute for Regenerative Medicine - which is in charge of implementing the 10-year, $2.95 billion state human embryonic stem cell research program approved under Proposition 71 - on Wednesday released a draft spending plan that "sets a strikingly modest tone" for outcomes of the research.
Package labels for Viagra, Cialis, and other erectile dysfunction drugs should inform patients that ED is a sign of potentially fatal artery disease, according to a petition the Physicians Committee for Responsible Medicine filed with the Food and Drug Administration on Feb. 10. Between 18 and 30 million men in the United States have ED.
Atara Biotherapeutics, Inc., a drug development company with a focus on innovative therapies for patients with debilitating diseases, announced today that it has secured $38.5 million in initial closings under its Series B financing. In this round, investors Amgen Ventures, Celgene Corporation, and EcoR1 Capital, joined existing investors Alexandria Venture Investments, DAG Ventures, Domain Associates, and Kleiner Perkins Caufield & Byers.
› Verified 4 days ago